SLC5A2 and type 2 diabetes mellitus: Glucose-lowering therapies exert heterogeneous mechanistic cardiovascular effects in T2DM, with the most consistent cardioprotective signatures observed for SGLT2 inhibitors and, to a lesser extent, GLP-1 receptor agonists.